Guca2b-KO 基因敲除小鼠

1. Nomiri, Samira, Hoshyar, Reyhane, Chamani, Elham, Silvestris, Nicola, Safarpour, Hossein. 2022. Prediction and validation of GUCA2B as the hub-gene in colorectal cancer based on co-expression network analysis: In-silico and in-vivo study. In Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 147, 112691. doi:10.1016/j.biopha.2022.112691. https://pubmed.ncbi.nlm.nih.gov/35151227/

2. Huang, Jason C, Li, Ming-Chun, Huang, I-Chieh, Lin, Wei-Zhi, Chang, Yu-Tien. 2024. Gene Coexpression and miRNA Regulation: A Path to Early Intervention in Colorectal Cancer. In Human gene therapy, 35, 855-867. doi:10.1089/hum.2023.207. https://pubmed.ncbi.nlm.nih.gov/38767504/

3. Yoshikawa, Yukie, Nakayama, Tomohiro, Saito, Kosuke, Soma, Masayoshi, Usami, Ron. . Haplotype-based case-control study of the association between the guanylate cyclase activator 2B (GUCA2B, Uroguanylin) gene and essential hypertension. In Hypertension research : official journal of the Japanese Society of Hypertension, 30, 789-96. doi:. https://pubmed.ncbi.nlm.nih.gov/18037771/

4. Brenna, Øystein, Bruland, Torunn, Furnes, Marianne W, Sandvik, Arne K, Gustafsson, Björn I. 2015. The guanylate cyclase-C signaling pathway is down-regulated in inflammatory bowel disease. In Scandinavian journal of gastroenterology, 50, 1241-52. doi:10.3109/00365521.2015.1038849. https://pubmed.ncbi.nlm.nih.gov/25979109/